当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > In vitro succinate dehydrogenase chemosensitivity of gastric carcinoma--relationship to DNA content.

In vitro succinate dehydrogenase chemosensitivity of gastric carcinoma--relationship to DNA content.

Abstract：

:Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was microspectrophotometrically determined. Following exposure of malignant tissue to carboquone (CQ) and cisplatin (DDP), the mean SD activity in cells displaying a relatively regular DNA distribution (type II) was significantly higher than that in those exhibiting a widely scattered DNA distribution (type IV; P less than 0.01 in CQ, P less than 0.05 in DDP). A similar tendency was recognized in cells that were treated with aclacinomycin A (ACR), Adriamycin (ADM), and mitomycin C (MMC). Such a decrease in SD activity in cells exhibiting a type IV pattern was remarkable, especially in cases undifferentiated adenocarcinoma. Mitotic counting analysis revealed a significantly higher value for DNA pattern type IV as compared with the findings for type II (P less than 0.01). These results demonstrate that gastric carcinoma displaying a high malignant potentially shows a better response to antitumor drugs. Adjuvant chemotherapy prescribed following drug-sensitivity testing should be effective against such tumors.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

doi

10.1007/BF00686250

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

185-9

issue

3

eissn

0344-5704

issn

1432-0843

journal_volume

29

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.

    abstract：PURPOSE:Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm. S-1 has been developed as a novel oral antineoplastic agent based on the modulation of 5-fluorouracil (5-FU) bioactivity. This study was conducted to investigate the preclinical therapeutic effect of S-1 on MPM. METHODS:We used three human MPM c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1503-x

    authors： Van TT,Hanibuchi M,Kakiuchi S,Sato S,Kuramoto T,Goto H,Mitsuhashi A,Nishioka Y,Akiyama S,Sone S

    更新日期：2011-08-01 00:00:00

  • Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.

    abstract：PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3009-7

    authors： Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

    更新日期：2016-05-01 00:00:00

  • Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.

    abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2862-0

    authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

    更新日期：2015-11-01 00:00:00

  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.

    abstract：:The effect of 7-alkyl substitutions on growth inhibition in seven Camptothecin (CPT) ring systems with various groups at the ten position was evaluated in three human breast cancer cell lines that model (1) hormone-sensitive (MCF-7/wt), (2) hormone insensitive (MDA-MB-231), or (3) alkylator-resistant (MCF-7/4-hc) form...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0007-6

    authors： Adams DJ,da Silva MW,Flowers JL,Kohlhagen G,Pommier Y,Colvin OM,Manikumar G,Wani MC

    更新日期：2006-01-01 00:00:00

  • Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells.

    abstract：:The mechanism of toxicity of 3-deazaguanosine was studied in a number of human tumor cell lines by determination of the effects of various purine compounds on the growth of the cells in the presence of the drug and by studies of the effects of 3-deazaguanosine on the metabolism of radiolabeled precursors in these cell...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257296

    authors： Page T,Jacobsen SJ,Smejkal RM,Scheele J,Nyhan WL,Mangum JH,Robins RK

    更新日期：1985-01-01 00:00:00

  • Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.

    abstract：PURPOSE:Although cisplatin is the drug of choice in treating lung cancer patients, relapse and resistance is a common drawback to its clinical effectiveness. Based on cisplatin's reported ability to interfere with numerous cellular components, including mitochondria, we probed alterations in metabolism in cisplatin-res...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2366-8

    authors： Sullivan EJ,Kurtoglu M,Brenneman R,Liu H,Lampidis TJ

    更新日期：2014-02-01 00:00:00

  • Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

    abstract：:Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686401

    authors： Kötting J,Berger MR,Unger C,Eibl H

    更新日期：1992-01-01 00:00:00

  • Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein.

    abstract：PURPOSE:The intra-tumour distribution of anticancer drugs remains an important, but often under-estimated, influence on drug efficacy. Tumour acidity and the presence of efflux pumps were examined for their influence on the distribution of doxorubicin in a solid tumour model. METHODS:Anticancer drug distribution and o...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1598-8

    authors： Mellor HR,Callaghan R

    更新日期：2011-11-01 00:00:00

  • A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.

    abstract：PURPOSE:The objectives of these analyses were to (1) develop a semimechanistic-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model to describe neutropenic response to pemetrexed and to (2) identify influential covariates with respect to pharmacodynamic response. PATIENTS AND METHODS:Data from 279 pati...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0077-5

    authors： Latz JE,Karlsson MO,Rusthoven JJ,Ghosh A,Johnson RD

    更新日期：2006-04-01 00:00:00

  • A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.

    abstract：PURPOSE:Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, M...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-014-2611-9

    authors： Wettergren Y,Taflin H,Odin E,Kodeda K,Derwinger K

    更新日期：2015-01-01 00:00:00

  • Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.

    abstract：:The pharmacokinetics and metabolism of 4-demethoxydaunorubicin (idarubicin, IDA) were studied in 21 patients with advanced cancer after i.v. (12 mg/m2) and oral (30-35 mg/m2) treatment according to a balanced crossover design. Patients were divided into four groups: subjects who showed normal liver and kidney function...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00686301

    authors： Camaggi CM,Strocchi E,Carisi P,Martoni A,Tononi A,Guaraldi M,Strolin-Benedetti M,Efthymiopoulos C,Pannuti F

    更新日期：1992-01-01 00:00:00

  • Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

    abstract：PURPOSE:This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS:Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0954-4

    authors： Izbicka E,Diaz A,Streeper R,Wick M,Campos D,Steffen R,Saunders M

    更新日期：2009-10-01 00:00:00

  • Adriamycin-lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma.

    abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00451648

    authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

    更新日期：1989-01-01 00:00:00

  • The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.

    abstract：PURPOSE:To study the dual mechanism of action of FD137, a 3,3-disubstituted nitrosourea designed to block signaling mediated by the epidermal growth factor receptor (EGFR) on its own and to be hydrolyzed to an inhibitor of EGFR plus a DNA-damaging species. MATERIALS AND METHODS:HPLC was used to determine the half-life...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-002-0524-5

    authors： Qiu Q,Dudouit F,Matheson SL,Brahimi F,Banerjee R,McNamee JP,Jean-Claude BJ

    更新日期：2003-01-01 00:00:00

  • Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymethotrexate in rabbits.

    abstract：:Anaesthetized rabbits were infused with methotrexate (MTX; 30 micrograms x kg-1 x min-1) for 4 h. Constant plasma concentrations of MTX and its main metabolite 7-hydroxymethotrexate (7-OH-MTX) were achieved 40-60 min after the start of the infusion. In all, 50% of the infused MTX was eliminated by the kidney; another ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF02897260

    authors： Iven H,Brasch H

    更新日期：1990-01-01 00:00:00

  • Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

    abstract：:While N-phosphonacetyl-L-aspartic acid (PALA), an inhibitor of de novo pyrimidine biosynthesis, demonstrated a unique spectrum of activity during preclinical drug evaluation, multiple clinical trials have shown it to possess minimal clinical activity. One explanation for the disappointing results is the possibility th...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00296262

    authors： Markman M,Chan TC,Cleary S,Howell SB

    更新日期：1987-01-01 00:00:00

  • Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.

    abstract：:Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CA...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00254574

    authors： Mead GM,Thompson J,Sweetenham JW,Buchanan RB,Whitehouse JM,Williams CJ

    更新日期：1987-01-01 00:00:00

  • Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer.

    abstract：:Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257124

    authors： Allan SG,Gregor A,Cornbleet MA,Leonard RC,Smyth JF,Grant IW,Crompton GK

    更新日期：1984-01-01 00:00:00

  • In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

    abstract：PURPOSE:In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung cancer (NSCLC). The aim of this study was to test whether paclitaxel followe...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1347-4

    authors： Cheng H,An SJ,Zhang XC,Dong S,Zhang YF,Chen ZH,Chen HJ,Guo AL,Lin QX,Wu YL

    更新日期：2011-03-01 00:00:00

  • MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents.

    abstract：PURPOSE:P-glycoprotein (P-gp), encoded by MDR1 (or ABCB1), is important in anticancer drug delivery and resistance. We evaluated alterations in P-gp-mediated transport of anticancer agents due to the MDR1 G1199A polymorphism. METHODS:Using stable recombinant epithelial cells expressing wild-type (MDR1 (wt)) or G1199A ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0906-4

    authors： Woodahl EL,Crouthamel MH,Bui T,Shen DD,Ho RJ

    更新日期：2009-06-01 00:00:00

  • Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.

    abstract：PURPOSE:Many cell lines resistant to cisplatin (DDP) have reduced DDP accumulation. We postulated that reduced accumulation of DDP in resistant cells might be due to decreased intracellular DDP binding, leading to increased passive efflux. METHODS:The total cellular ([T-DDP]), intracellular ultrafiltrable ([F-DDP]) an...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050967

    authors： Chau Q,Stewart DJ

    更新日期：1999-01-01 00:00:00

  • In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts.

    abstract：:New active drugs are needed for the treatment of primary brain tumors in both children and adults. S16020 is a cytotoxic olivacine derivative that inhibits topoisomerase II. The aim of the study was to determine its antitumor activity in athymic mice bearing subcutaneous medulloblastoma (IGRM33, 34, 57) and glioblasto...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0584-1

    authors： Vassal G,Merlin JL,Terrier-Lacombe MJ,Grill J,Parker F,Sainte-Rose C,Aubert G,Morizet J,Sévenet N,Poullain MG,Lucas C,Kalifa C

    更新日期：2003-05-01 00:00:00

  • Modulation of mitomycin C-induced multidrug resistance in vitro.

    abstract：:A series of in vitro cytotoxicity studies were performed to achieve pharmacologic reversal of resistance to the alkylating agent mitomycin (MMC) in L-1210 leukemia cells. A multidrug-resistant (MDR), P-glycoprotein-positive cell line, RL-1210/.1 [11], was exposed to potential MDR modulators in the absence or presence ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685114

    authors： Dorr RT,Liddil JD

    更新日期：1991-01-01 00:00:00

  • 5-Fluorouracil disrupts ovarian preantral follicles in young C57BL6J mice.

    abstract：PURPOSE:5-Fluorouracil (5-FU), an anti-cancer drug, has been used for hepatoblastoma (HB) chemotherapy in children, who may have impaired  ovarian follicle pool reserve with lasting effects to reproduction. Therefore, this study aimed to investigate 5-FU effects on survival, growth, and morphology of ovarian preantral ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-020-04217-7

    authors： Almeida JZ,Lima LF,Vieira LA,Maside C,Ferreira ACA,Araújo VR,Duarte ABG,Raposo RS,Báo SN,Campello CC,Oliveira LFS,da Costa TP,Abreu JG,Figueiredo JR,Oriá RB

    更新日期：2021-01-20 00:00:00

  • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

    abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-020-04085-1

    authors： He G,Xie X,Siddik ZH

    更新日期：2020-06-01 00:00:00

  • Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.

    abstract：:A total of 40 patients with recurrent non-Hodgkin's lymphoma were treated with ABEP combination chemotherapy (aclarubicin, N4-behenoyl-1-beta-D-arabinofuranosylcytosine, etoposide, and prednisolone). A complete remission (CR) was achieved in 37.5% of the patients and partial remission, in 15.0%. The ABEP regimen prove...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00692354

    authors： Yoshida T,Nakamura S,Ohtake S,Kobayashi K,Kanno M,Matsuda T,Matano S,Kondo K,Okafuji K,Kanai M

    更新日期：1989-01-01 00:00:00

  • A reliable method to determine which candidate chemotherapeutic drugs effectively inhibit tumor growth in patient-derived xenografts (PDX) in single mouse trials.

    abstract：PURPOSE:We report on a statistical method for grouping anti-cancer drugs (GRAD) in single mouse trials (SMT). The method assigns candidate drugs into groups that inhibit or do not inhibit tumor growth in patient-derived xenografts (PDX). It determines the statistical significance of the group assignments without replic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03942-y

    authors： Gordon D,Axelrod DE

    更新日期：2019-12-01 00:00:00

  • Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.

    abstract：PURPOSE:The purpose of this study was to evaluate the expression of ser-miRNAs at different periods during treatment and analyze their relationship with therapeutic response and prognosis in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab (NCCT). METHODS:Venous blood w...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03937-9

    authors： Liu B,Su F,Lv X,Zhang W,Shang X,Zhang Y,Zhang J

    更新日期：2019-11-01 00:00:00

  • Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.

    abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-009-0991-z

    authors： Saban N,Bujak M

    更新日期：2009-07-01 00:00:00

  • A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

    abstract：BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS:Twenty patients received one dos...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1779-5

    authors： Chao J,Synold TW,Morgan RJ Jr,Kunos C,Longmate J,Lenz HJ,Lim D,Shibata S,Chung V,Stoller RG,Belani CP,Gandara DR,McNamara M,Gitlitz BJ,Lau DH,Ramalingam SS,Davies A,Espinoza-Delgado I,Newman EM,Yen Y

    更新日期：2012-03-01 00:00:00